Celesia, A.; Notaro, A.; Franzò, M.; Lauricella, M.; D’Anneo, A.; Carlisi, D.; Giuliano, M.; Emanuele, S.
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis. Biomedicines 2022, 10, 1994.
https://doi.org/10.3390/biomedicines10081994
AMA Style
Celesia A, Notaro A, Franzò M, Lauricella M, D’Anneo A, Carlisi D, Giuliano M, Emanuele S.
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis. Biomedicines. 2022; 10(8):1994.
https://doi.org/10.3390/biomedicines10081994
Chicago/Turabian Style
Celesia, Adriana, Antonietta Notaro, Marzia Franzò, Marianna Lauricella, Antonella D’Anneo, Daniela Carlisi, Michela Giuliano, and Sonia Emanuele.
2022. "The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis" Biomedicines 10, no. 8: 1994.
https://doi.org/10.3390/biomedicines10081994
APA Style
Celesia, A., Notaro, A., Franzò, M., Lauricella, M., D’Anneo, A., Carlisi, D., Giuliano, M., & Emanuele, S.
(2022). The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis. Biomedicines, 10(8), 1994.
https://doi.org/10.3390/biomedicines10081994
